Yahoo
    NasdaqGS - Delayed Quote USD

    Geron Corporation (GERN)

    1.5700 +0.0600 (+3.97%)
    At close: September 4 at 4:00:01 PM EDT
    1.5691 -0.0009 (-0.06%)
    After hours: September 4 at 7:48:32 PM EDT
    Trade Geron on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for GERN

    What's happening with GERN?

    56m ago     Powered by Yahoo Scout

    Geron Corporation is gaining attention with its upcoming presentations at major investor conferences and solid Q2 earnings results. The company continues to focus on expanding the market for its hematology drug RYTELO (imetelstat), which has shown promising revenue growth.

    Powered by Yahoo Scout
    • Previous Close 1.5100
    • Open 1.4900
    • Bid 1.3400 x 100
    • Ask 1.8200 x 100
    • Day's Range 1.4600 - 1.5900
    • 52 Week Range 1.0400 - 2.0100
    • Volume 11,477,760
    • Avg. Volume 11,814,309
    • Market Cap (intraday) 1.009B
    • Beta (5Y Monthly) 0.61
    • PE Ratio (TTM) --
    • EPS (TTM) -0.1100
    • Earnings Date Nov 4, 2026
    • Forward Dividend & Yield --
    • Ex-Dividend Date --
    • 1y Target Est 4.25

    Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

    www.geron.com

    258

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Geron Corporation

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    GERN
    18.94%
    S&P 500 (^GSPC)
    12.75%

    1-Year Return

    GERN
    13.77%
    S&P 500 (^GSPC)
    18.71%

    3-Year Return

    GERN
    36.69%
    S&P 500 (^GSPC)
    70.93%

    5-Year Return

    GERN
    9.03%
    S&P 500 (^GSPC)
    70.18%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 57.48M
    Earnings -16.68M
    Profit Margin -29.02%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -20M
    0
    20M
    40M
    -60.0%
    -50.0%
    -40.0%
    -30.0%
    -20.0%
    -10.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    3.00
    4.25 Average
    1.5700 Current
    6.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 11/5/2025
    Analyst Needham
    Rating Action Maintains
    Rating Buy
    Price Action Lowers
    Price Target 5 -> 4
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (5yr expected)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -33.05%

    • Return on Assets (ttm)

      -4.11%

    • Return on Equity (ttm)

      -28.28%

    • Revenue (ttm)

      204.56M

    • Net Income Avi to Common (ttm)

      -67.61M

    • Diluted EPS (ttm)

      -0.1100

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      300.85M

    • Total Debt/Equity (mrq)

      55.87%

    • Levered Free Cash Flow (ttm)

      -78.37M

    View More

    Compare

    Compare

    Select to analyze similar companies using key performance metrics; select up to 4 stocks.

    GERN
    Geron Corporation
    1.5700
    +3.97%
    Mkt Cap 1.009B
    Industry -
    SER
    Mkt Cap undefined -
    Industry -
    LIMN
    Mkt Cap undefined -
    Industry -
    VIVS
    Mkt Cap undefined -
    Industry -
    SGMO
    Mkt Cap undefined -
    Industry -
    MAIA
    Mkt Cap undefined -
    Industry -
    PBM
    Mkt Cap undefined -
    Industry -
    ANL
    Mkt Cap undefined -
    Industry -
    ATOS
    Mkt Cap undefined -
    Industry -
    GUTS
    Mkt Cap undefined -
    Industry -
    ALT
    Mkt Cap undefined -
    Industry -

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    STEM Stem, Inc.
    5.57 +1.09%
    AGEN Agenus Inc.
    8.24 0.00%
    EXEL Exelixis, Inc.
    59.01 -0.20%
    INCY Incyte Corporation
    126.75 -0.98%
    BCRX BioCryst Pharmaceuticals, Inc.
    9.96 -1.29%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: